Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 17 AUGUST 2026

California Cannabis Contracts After Rescheduling: Why Your Contracts Need A Second Look

Harris Sliwoski
Explore more from Harris Sliwoski

Cannabis rescheduling has fundamentally altered the regulatory landscape for California operators, creating hidden risks in contracts drafted before April 2026. Supply agreements, licensing deals, and investment documents built around Schedule I assumptions may now contain critical gaps regarding DEA registration requirements, medical versus adult-use distinctions, and tax treatment under I.R.C. 280E.

United StatesCannabis & Hemp
Jared Schwass
Jared Schwass
Author LinkedIn connections

California Cannabis Contracts After Rescheduling: Why Your Contracts Need a Second Look

Rescheduling did not just change tax treatment and licensing options for cannabis operators. It also changed the assumptions baked into thousands of existing cannabis contracts. Supply agreements, licensing arrangements, and investment documents drafted before April 2026 were built around a world where cannabis was federally illegal in every respect. That world no longer exists for qualifying medical activity, and many of those older contracts were never written to handle the change.

This creates a quiet, but serious, risk. A contract that looked airtight eighteen months ago may now contain gaps, outdated assumptions, or ambiguous triggers that leave one party exposed. Before signing a new deal or relying on an old one, California operators should take a hard look at how rescheduling, DEA registration, and DCC license restructuring interact with their existing contracts.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

See more popular content from

Article

The Intoxicating Hemp Products Ban Was Delayed A Month. Now What?

The House has passed a short-term funding bill postponing the federal ban on hemp-derived THC products from November 12th to December 11th. With comprehensive legislation unlikely before the new deadline and competing interests from cannabis sellers, alcohol producers, and state regulators creating policy gridlock, the future of intoxicating hemp products remains uncertain as midterm elections approach.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski
Article

IRC Section 280E And Cannabis Tax Planning: Recent Developments And Practical Considerations

The landscape surrounding Section 280E of the Internal Revenue Code continues to evolve with President Trump's Executive Order on medical marijuana rescheduling, advancing litigation in New Mexico Top Organics v. Commissioner, and shifting regulatory signals. Cannabis taxpayers face critical decisions about taking "non-280E" positions on their tax returns while the IRS maintains its enforcement stance and the U.S. Tax Court case addressing common arguments remains pending.
United StatesCannabis & Hemp
Foley Hoag LLP
Foley Hoag LLP
Article

"Marijuana" Rescheduling Delayed, Again. What It Could Mean, And What Comes Next

The DEA's marijuana rescheduling hearing has been unexpectedly stayed following a motion to admit a new GAO report examining agency scheduling procedures. With the proceeding on hold and the medical marijuana Schedule III order facing legal challenges in the D.C. Circuit, the cannabis industry's path to federal tax relief through rescheduling has become increasingly uncertain.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski